Reimbursement

In the first part of this Q&A, Kathy Oubre, MS, discusses how likely it is that the most favored nation executive order will lead to price reductions in prescription drugs.

Under the second Trump administration, CMMI has published far more detail about peformance of Enhancing Oncology Model participants than under an earlier model, which spanned the administrations of 3 presidents.

A new report found that 9 of 10 small- to midsize businesses are not sure they will be able to provide health benefits to their employees in the near future.

Health insurers commit to reforming prior authorization processes, aiming to enhance patient care and reduce burdens on providers, impacting millions.

The author discusses how Principal Care Management (PCM) enhances oncology care, improves patient outcomes, and boosts reimbursement opportunities for providers, yet remains underutilized.

Given the track record of good outcomes and savings, policy leaders must do more to promote growth of for-profit PACE programs, the author asserts.

Alina Salganicoff, PhD, discusses the immediate effects of the budget cuts to Medicaid as it pertains to women's health across the country.

Proposed changes to the Physician Fee Schedule aim to support community oncology, but the Inflation Reduction Act threatens financial stability for practices.

A new survey reveals widespread consumer frustration with prior authorization, highlighting the need for urgent reform in insurance coverage.

Patients face increasing barriers to healthcare access as physician shortages rise and Medicare payment systems fail to support independent practices.

The Supreme Court decision in Medina v Planned Parenthood South Atlantic and the subsequent passing of the budget bill leave Planned Parenthood clinics and their patients in a precarious spot, says Danika Severino Wynn, CNM.

Christine Pfaff, MBA, RPh, joins COA as director of clinical initiatives, enhancing support for community oncology practices and pharmacy operations amid health care challenges.

CMS proposes the 2026 Physician Fee Schedule (PFS), addressing payment disparities in oncology, but the community oncology community warns of financial threats from the Inflation Reduction Act. Updates reflect late Tuesday release of the proposed 2026 schedule for the Hospital Outpatient Prospective Payment System.

Medicare inflation rebates fail to curb rising drug prices, highlighting the need for further policy action to control costs.

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining operations, while addressing challenges in data accuracy and equity, said speakers at the Tennessee Oncology “Tech Innovations in Community Oncology."

Artificial intelligence (AI) will transform community oncology, addressing workforce shortages and reimbursement challenges while enhancing patient care and operational efficiency, discussed speakers at Tennessee Oncology's “Tech Innovations in Community Oncology."

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage cancer care over time.

Ted Okon, MBA, of the Community Oncology Alliance discusses how community oncology faces a revenue crisis due to the Inflation Reduction Act's impact on Medicare reimbursement, risking patient access to vital cancer treatments.

South Carolina had previously barred abortion clinics, including Planned Parenthood, from participating in Medicaid, leaving many patients vulnerable to uncovered treatment.

The National Comprehensive Cancer Network (NCCN) policy summit highlighted the need for improved communication between oncology and primary care to enhance cancer survivor outcomes and care transitions.

The Inflation Reduction Act (IRA) may be restricting Medicare Part D formularies, increasing patient costs, and stifling pharmaceutical innovation, experts warned at the Academy of Managed Care Pharmacy 2025 annual meeting.

Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.

The design of the Enhancing Oncology Model (EOM) was a perfect fit for Minnesota Oncology.

Independent pharmacies have filed 3 class action lawsuits against GoodRx Holdings and major pharmacy benefit managers (PBMs).